Table 1.
Baseline Demographics of Control Subjects and Patients With COPD
| Demographic | Control (N = 12) | COPD (N = 12) | P Value |
|---|---|---|---|
| Age, y | 58.0 (53.8-62.3) | 68.6 (64.8-73.0) | .004a |
| Sex, male:female | 3:9 | 12:0 | … |
| BMI | 21.8 (21.2-23.2) | 22.6 (20.0-24.5) | .885 |
| Smoking history, pack-years | … | 75.5 (47.6-111.8) | … |
| FEV1, L | 2.54 (2.30-2.99) | 2.07 (1.76-2.62) | .110 |
| %FEV1, % | 107.7 (97.8-119.9) | 74.4 (60.9-84.4) | < .001a |
| FVC, L | 3.23 (2.87-4.06) | 3.69 (3.04-4.04) | .314 |
| %FVC, % | 103.3 (97.5-114.1) | 104.5 (96.8-114.8) | .904 |
| FEV1/FVC | 78.6 (73.7-80.9) | 60.0 (49.6-65.1) | < .001a |
| GOLD stage, I/II/III/IV | … | 5/5/2/0 | … |
| Tiotropium, % | … | 16.7 | … |
| Salmeterol, % | … | 25.0 | … |
Data are expressed as medians (25th and 75th percentiles). %FEV1 = percentage of predicted FEV1; %FVC = percentage of predicted FVC; GOLD = Global Initiative for Chronic Obstructive Lung Disease.
a
Statistically significant, P < .05.